Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: natural killer cells based therapeutics - Mendus

Drug Profile

Research programme: natural killer cells based therapeutics - Mendus

Latest Information Update: 29 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mendus
  • Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 May 2023 Reseaerch programme: natural killer cells-based therapeutics - Mendus is available for licensing as of 21 May 2023. https://immunicum-uploads-prod.s3.amazonaws.com/uploads/2023/04/Mendus_AnnualReport_2022_04_17b.pdf
  • 11 Nov 2022 Preclinical trials in Cancer in Sweden (Parenteral) (before November 2022)
  • 11 Nov 2022 Pharmadynamics data from preclinical studies presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top